CN106715469B - 抗体、组合物和用途 - Google Patents

抗体、组合物和用途 Download PDF

Info

Publication number
CN106715469B
CN106715469B CN201580052144.4A CN201580052144A CN106715469B CN 106715469 B CN106715469 B CN 106715469B CN 201580052144 A CN201580052144 A CN 201580052144A CN 106715469 B CN106715469 B CN 106715469B
Authority
CN
China
Prior art keywords
antibody
seq
set forth
agent
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580052144.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106715469A (zh
Inventor
乃-功·V·张
马希乌丁·艾哈迈德
赵琪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN106715469A publication Critical patent/CN106715469A/zh
Application granted granted Critical
Publication of CN106715469B publication Critical patent/CN106715469B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201580052144.4A 2014-08-27 2015-08-26 抗体、组合物和用途 Active CN106715469B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462042457P 2014-08-27 2014-08-27
US62/042,457 2014-08-27
PCT/US2015/047013 WO2016033225A2 (en) 2014-08-27 2015-08-26 Antibodies, compositions, and uses

Publications (2)

Publication Number Publication Date
CN106715469A CN106715469A (zh) 2017-05-24
CN106715469B true CN106715469B (zh) 2021-10-22

Family

ID=55400815

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580052144.4A Active CN106715469B (zh) 2014-08-27 2015-08-26 抗体、组合物和用途

Country Status (12)

Country Link
US (1) US10316093B2 (enExample)
EP (1) EP3186277B1 (enExample)
JP (1) JP6925264B2 (enExample)
KR (1) KR102485788B1 (enExample)
CN (1) CN106715469B (enExample)
AU (1) AU2015306621B2 (enExample)
BR (1) BR112017003582B1 (enExample)
CA (1) CA2959356C (enExample)
EA (1) EA038798B1 (enExample)
ES (1) ES2838750T3 (enExample)
WO (1) WO2016033225A2 (enExample)
ZA (1) ZA201701168B (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10865245B2 (en) 2014-12-23 2020-12-15 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
WO2016106004A1 (en) 2014-12-23 2016-06-30 Full Spectrum Genetics, Inc. Novel anti-b7h3 binding compounds and uses thereof
CA2990411A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
US20190300606A1 (en) * 2016-07-01 2019-10-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory Immune Receptor Inhibition Methods and Compositions
US11517627B2 (en) 2017-01-20 2022-12-06 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
CN109843927B (zh) * 2017-03-06 2022-06-21 江苏恒瑞医药股份有限公司 抗b7-h3抗体、其抗原结合片段及其医药用途
WO2018177393A1 (zh) 2017-03-31 2018-10-04 江苏恒瑞医药股份有限公司 B7-h3抗体、其抗原结合片段及其医药用途
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
EA201992683A1 (ru) * 2017-05-12 2020-04-23 Мемориал Слоан-Кеттеринг Кэнсер Сентер Применение антител против b7h3 для лечения злокачественных опухолей в центральной нервной системе
CN109963591B (zh) * 2017-08-04 2023-04-04 江苏恒瑞医药股份有限公司 B7h3抗体-药物偶联物及其医药用途
JP2020530454A (ja) 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 安全な細胞治療薬を生成するためのプラットフォーム
US11199371B2 (en) 2017-08-17 2021-12-14 Michael D. Miller Firearm assembly system and method
MX2020002667A (es) 2017-09-08 2020-08-03 Maverick Therapeutics Inc Proteinas de unión condicionalmente activadas restringidas.
CN117106096A (zh) * 2017-10-26 2023-11-24 盛禾(中国)生物制药有限公司 新的重组融合蛋白及其制备和用途
CA3080835A1 (en) 2017-10-31 2019-05-09 Pantarhei Bioscience B.V. Immunotherapeutic methods for treating and/or preventing lung cancer
CN109939126A (zh) * 2017-12-21 2019-06-28 张曼 Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用
CN109939231A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用
JP7366908B2 (ja) 2018-01-15 2023-10-23 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｐｄ－１に対する単一ドメイン抗体及びその変異体
AU2019206207B2 (en) * 2018-01-15 2025-04-10 Stichting Sanquin Bloedvoorziening Factor H potentiating antibodies and uses thereof
IL323061A (en) 2018-04-11 2025-10-01 Inhibrx Biosciences Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
WO2019225787A1 (ko) * 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
CN112789294A (zh) 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
US12274759B2 (en) 2018-08-23 2025-04-15 Regents Of The University Of Minnesota Affibody proteins specific for B7-H3 (CD276)
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020076970A1 (en) * 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
JP7374440B2 (ja) * 2018-11-22 2023-11-07 スージョウ カノヴァ バイオファーマシューティカル カンパニーリミテッド 抗ｂ７－ｈ３抗体
CN120484127A (zh) * 2019-03-05 2025-08-15 武田药品工业有限公司 受约束的条件性活化的结合蛋白
CN109929039A (zh) * 2019-03-28 2019-06-25 郑州大学第一附属医院 基于cd276抗体的嵌合抗原受体、慢病毒表达载体及其应用
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US20220235134A1 (en) * 2019-05-28 2022-07-28 Single Cell Technology, Inc. Anti-b7-h3 antibodies
CA3142634A1 (en) * 2019-07-03 2021-01-07 Crystal Bioscience Inc. Anti-b7-h3 antibody and methods of use thereof
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
KR20220057530A (ko) 2019-07-17 2022-05-09 제미니 테라퓨틱스 서브, 인코포레이티드 인자 h 강화 항체 및 이의 용도
EP4022313A1 (en) 2019-08-30 2022-07-06 Y-Mabs Therapeutics, Inc. Immunohistochemical assessment of b7-h3 expression
CN110642948B (zh) * 2019-10-09 2021-06-29 达石药业(广东)有限公司 B7-h3纳米抗体、其制备方法及用途
AU2020387401A1 (en) * 2019-11-18 2022-05-26 Board Of Regents, The University Of Texas System Anti-B7-H3 monoclonal antibody and methods of use thereof
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4138931A1 (en) * 2020-04-24 2023-03-01 Y-Mabs Therapeutics, Inc. B7h3 antibodies with chelators
WO2021244721A1 (en) 2020-06-04 2021-12-09 Y-Mabs Therapeutics, Inc. Anti-b7h3 antibodies for the treatment of cancer
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CN112961241B (zh) * 2020-06-30 2022-04-22 广州百暨基因科技有限公司 抗b7h3抗体及其应用
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
EP4269435A4 (en) * 2020-12-23 2025-06-18 Fortvita Biologics (Singapore) Pte. Ltd. ANTI-B7-H3 ANTIBODIES AND USES THEREOF
KR20230145038A (ko) 2021-02-09 2023-10-17 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 생물활성 물질 접합체, 이의 제조방법 및 이의 용도
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
JP2024531790A (ja) * 2021-09-18 2024-08-29 スカイライン、セラピューティクス、リミテッド Ｗｅｔ－ＡＭＤの遺伝子療法のためのＡＡＶ
US20250230244A1 (en) * 2021-10-05 2025-07-17 Board Of Regents, The University Of Texas System Methods and compositions comprising b7-h3 binding polypetides
US20250092140A1 (en) * 2022-01-14 2025-03-20 Shenghe (China) Biopharmaceutical Co., Ltd. Bispecific antibody binding to b7h3 and nkp30, and application thereof
EP4480499A1 (en) 2022-02-16 2024-12-25 Medilink Therapeutics (Suzhou) Co., Ltd. Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
JP2025509832A (ja) 2022-03-15 2025-04-11 コンピュジェン リミテッド Ｉｌ－１８ｂｐアンタゴニスト抗体、並びに癌の治療での単剤療法及び併用療法におけるそれらの使用
CN116836281A (zh) * 2022-03-25 2023-10-03 英诺湖医药(杭州)有限公司 B7h3抗体及包含其的双功能抗体
CN119212733A (zh) 2022-05-18 2024-12-27 苏州宜联生物医药有限公司 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
TW202402808A (zh) * 2022-05-18 2024-01-16 中國大陸商上海藥明生物技術有限公司 抗-b7h3抗體及其用途
WO2024037627A1 (zh) * 2022-08-19 2024-02-22 盛禾(中国)生物制药有限公司 一种双特异性抗体及其应用
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
CN115819608A (zh) * 2022-10-08 2023-03-21 盛禾(中国)生物制药有限公司 一种纯化融合蛋白的方法
CN115845047A (zh) * 2022-11-07 2023-03-28 盛禾(中国)生物制药有限公司 一种异源二聚体蛋白质组合物
WO2024106939A1 (ko) * 2022-11-15 2024-05-23 주식회사 셀랩메드 B7-h3에 특이적으로 결합하는 항체
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025129565A1 (zh) * 2023-12-21 2025-06-26 西湖实验室(生命科学和生物医学浙江省实验室) 一种cd276迷你结合蛋白及其突变体及应用
WO2025245264A1 (en) * 2024-05-21 2025-11-27 Briapro Therapeutics Corp. Anti-b7-h3 antibodies and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687021A (zh) * 2007-03-22 2010-03-31 斯隆-凯特琳癌症研究院 单克隆抗体8h9的应用
EP1572077B1 (en) * 2002-03-08 2010-12-01 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8h9

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7666424B2 (en) 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US9150656B2 (en) * 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
AU2011268110B2 (en) 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
WO2016106004A1 (en) * 2014-12-23 2016-06-30 Full Spectrum Genetics, Inc. Novel anti-b7h3 binding compounds and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572077B1 (en) * 2002-03-08 2010-12-01 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8h9
CN101687021A (zh) * 2007-03-22 2010-03-31 斯隆-凯特琳癌症研究院 单克隆抗体8h9的应用

Also Published As

Publication number Publication date
JP2017532952A (ja) 2017-11-09
EP3186277A4 (en) 2018-01-17
NZ729451A (en) 2024-08-30
AU2015306621A1 (en) 2017-03-16
ES2838750T3 (es) 2021-07-02
US10316093B2 (en) 2019-06-11
US20170240637A1 (en) 2017-08-24
CA2959356C (en) 2024-02-20
BR112017003582B1 (pt) 2024-01-09
BR112017003582A2 (pt) 2018-02-27
CN106715469A (zh) 2017-05-24
CA2959356A1 (en) 2016-03-03
JP6925264B2 (ja) 2021-08-25
WO2016033225A3 (en) 2016-04-21
ZA201701168B (en) 2021-05-26
EP3186277A2 (en) 2017-07-05
EP3186277B1 (en) 2020-10-07
AU2015306621B2 (en) 2021-05-06
KR102485788B1 (ko) 2023-01-09
KR20170042786A (ko) 2017-04-19
EA201790465A1 (ru) 2017-07-31
WO2016033225A2 (en) 2016-03-03
EA038798B1 (ru) 2021-10-21

Similar Documents

Publication Publication Date Title
CN106715469B (zh) 抗体、组合物和用途
JP5951850B2 (ja) 改良された抗ｃｄ１９抗体
CN110545845B (zh) 抗cd33抗体药剂
JP4733635B2 (ja) 抗ｃｄ１９抗体
JP6046642B2 (ja) Ｃｅａ抗体
US10988534B2 (en) Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof
US20150191543A1 (en) Engineered antibody fragments for targeting and imaging cd8 expression in vivo
TWI874314B (zh) 螯合型放射核種之抗體
CA3045466A1 (en) Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
JP7759348B2 (ja) がんの治療のための抗ｂ７ｈ３抗体
CN115996951A (zh) 抗cd103抗体
US20240166768A1 (en) Anti-matrix metalloproteinase-14 antibodies for the treatment of cancer
HK1235068B (en) Antibodies, compositions, and uses
HK1235068A1 (en) Antibodies, compositions, and uses
HK40088388B (zh) 针对cll1的抗体及其用途
HK40088388A (zh) 针对cll1的抗体及其用途
IL285313A (en) Antibodies for cancer treatment
HK40090440A (zh) 抗叶酸受体1抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant